Baseline characteristics of subjects with newly diagnosed AML (de novo or secondary to MDS), unfit for standard therapy
| . | Variables, n = 11 . |
|---|---|
| Age, y | |
| Median (range) | 78.0 (70-88) |
| Age ≥75, n (%) | 8 (72.7) |
| Age ≥80, n (%) | 5 (45.5) |
| Sex, n (%) | |
| M | 6 (54.5) |
| F | 5 (45.5) |
| AML type, n (%) | |
| De novo | 3 (27.3) |
| Secondary to MDS | 8 (72.7) |
| Prior HMA treatment of MDS | 5 (45.5) |
| ELN score, n (%) | |
| Favorable | 1 (9.1) |
| Intermediate | 4 (36.4) |
| Adverse | 6 (54.5) |
| ECOG PS, n (%) | |
| 0 | 4 (36.4) |
| 1 | 5 (45.5) |
| 2 | 2 (18.2) |
| BM blast percentage | |
| Median (range) | 80.0 (22-100) |
| 20%-30%, n (%) | 1 (9.1) |
| 31%-50%, n (%) | 3 (27.3) |
| >50%, n (%) | 7 (63.6) |
| White blood cells, ×109/L | |
| Median | 4.3 |
| Range | 0.8-61.8 |
| . | Variables, n = 11 . |
|---|---|
| Age, y | |
| Median (range) | 78.0 (70-88) |
| Age ≥75, n (%) | 8 (72.7) |
| Age ≥80, n (%) | 5 (45.5) |
| Sex, n (%) | |
| M | 6 (54.5) |
| F | 5 (45.5) |
| AML type, n (%) | |
| De novo | 3 (27.3) |
| Secondary to MDS | 8 (72.7) |
| Prior HMA treatment of MDS | 5 (45.5) |
| ELN score, n (%) | |
| Favorable | 1 (9.1) |
| Intermediate | 4 (36.4) |
| Adverse | 6 (54.5) |
| ECOG PS, n (%) | |
| 0 | 4 (36.4) |
| 1 | 5 (45.5) |
| 2 | 2 (18.2) |
| BM blast percentage | |
| Median (range) | 80.0 (22-100) |
| 20%-30%, n (%) | 1 (9.1) |
| 31%-50%, n (%) | 3 (27.3) |
| >50%, n (%) | 7 (63.6) |
| White blood cells, ×109/L | |
| Median | 4.3 |
| Range | 0.8-61.8 |